Market Cap 17.42M
Revenue (ttm) 0.00
Net Income (ttm) -26.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 81,700
Avg Vol 148,730
Day's Range N/A - N/A
Shares Out 15.98M
Stochastic %K 24%
Beta -1.73
Analysts Sell
Price Target $11.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating va...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
josegodoy
josegodoy Jul. 4 at 11:04 AM
$TPST no one knows where she’s going, PERIOD on the daily candle - looking for a break of the red descending line - this goes below $1 significantly (IMO) What was the October 2023 low….$0.23?…whatever If you need to write down why you bought this and have it front and center (read it daily) NO ONE KNOWS WHERE SHE’S GOING, PERIOD An opinion
0 · Reply
lousjamsession
lousjamsession Jul. 4 at 5:52 AM
0 · Reply
HectorNumba9
HectorNumba9 Jul. 3 at 4:52 PM
$TPST I dont see dilution. I see it moving with the economy. If u are here for a pump. You're in the wrong fucking stock😂😂😂i told u 100 times. Its buyout or die OMG I repeat
2 · Reply
lousjamsession
lousjamsession Jul. 3 at 1:25 PM
3 · Reply
joeydidntknowie
joeydidntknowie Jul. 2 at 10:30 PM
$TPST my take on this stock basically is with a significant catalyst it could really move. It has before. Until the catalyst happens there will probably be more pain in the form of dilution that we are accustomed to. I’ve decided to accumulate shares and average down because I believe in the value of the assets but I could definitely be completely wrong. People speculate as to the timing. Well …if only we knew. And it could be that the value of the assets isn’t much in which case we are in for a dilution mill — I doubt it but it’s possible. High risk high reward.
0 · Reply
josegodoy
josegodoy Jul. 2 at 9:41 PM
$TPST NO ONE KNOWS WHERE SHE’S GOING (period) Charts - simple line WEEKLY Chart I: the sign? - small break of the descending trend-line and too weak to break back (up) above it (too weak to even attempt to break back above it) - is it the tell of the up coming discount? = YES (my opinion) Chart II: the work up - I expect a significant discount over the next 8-10 weeks (in fact, I think we’ve already enter into it) THE RECOVERY 1) Historic: early-to-mid October holds historic significance (in terms of recovery) - positive data read-out 2) chart based ESTIMATE: approx Week of august 10 (recovery)….historically, recovery for this puppy means 4,000% - anticipated asset sale
2 · Reply
lousjamsession
lousjamsession Jul. 2 at 5:32 PM
$TPST @joeydidntknowie @WallStreetIsNotEasy
1 · Reply
joeydidntknowie
joeydidntknowie Jul. 2 at 5:11 AM
$TPST I hold 100k shares in this stock as of now. I have averaged down over months. I’m down about $50K. I’m not buying more and I’m not selling. We will see.
5 · Reply
josegodoy
josegodoy Jul. 1 at 8:43 PM
$TPST Just blocked Michl2000
3 · Reply
lgb2
lgb2 Jul. 1 at 4:48 PM
$TPST Tempest therapeutics names the tooth fairy as CEO
1 · Reply
Latest News on TPST
Tempest Therapeutics Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 26 days ago

Tempest Therapeutics Proxy statement: Proxy filing


Tempest Therapeutics Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 5 weeks ago

Tempest Therapeutics Proxy statement: Proxy filing


Tempest Therapeutics Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 7 weeks ago

Tempest Therapeutics Earnings release: Q1 2026


Tempest Therapeutics Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 7 weeks ago

Tempest Therapeutics Quarterly report: Q1 2026


Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026, 7:00 AM EDT - 2 months ago

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting


Tempest Therapeutics Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 2 months ago

Tempest Therapeutics Slides: Corporate presentation


Tempest Therapeutics Annual report: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 3 months ago

Tempest Therapeutics Annual report: Q4 2025


Tempest Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 3 months ago

Tempest Therapeutics Earnings release: Q4 2025


Tempest Therapeutics Registration statement: Registration filing

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Tempest Therapeutics Registration statement: Registration filing


Tempest Therapeutics Proxy statement: Proxy Filing

Dec 31, 2025, 7:00 AM EST - 6 months ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Dec 2, 2025, 7:00 AM EST - 7 months ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Nov 19, 2025, 7:00 AM EST - 8 months ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 9:00 AM EST - 8 months ago

Tempest Therapeutics Quarterly report: Q3 2025


Tempest Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 9:00 AM EST - 8 months ago

Tempest Therapeutics Earnings release: Q3 2025


Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

2025-11-05T13:36:56.000Z - 8 months ago

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year


Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

2025-08-11T20:55:19.000Z - 11 months ago

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)


Tempest Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Tempest Therapeutics Quarterly report: Q2 2025


Tempest Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Tempest Therapeutics Earnings release: Q2 2025


Tempest Therapeutics receives ODD from EMA for amezalpat

2025-06-05T12:05:21.000Z - 1 year ago

Tempest Therapeutics receives ODD from EMA for amezalpat


Tempest Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q1 2025


Tempest Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q1 2025


Tempest Therapeutics Slides: Corporate Presentation

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Tempest Therapeutics Slides: Corporate Presentation


Tempest Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Annual report: Q4 2024


Tempest Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q4 2024


Tempest Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Earnings release: Q3 2024


Tempest Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Quarterly report: Q3 2024


Tempest Therapeutics Proxy statement: Proxy Filing

Nov 12, 2024, 7:00 AM EST - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q2 2024


Tempest Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q2 2024


Tempest Therapeutics Transcript: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Update


Tempest Therapeutics Slides: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Slides: Study Update


Tempest Therapeutics Press release: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Press release: Study Update


Tempest Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q1 2024


Tempest Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q1 2024


Tempest Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Earnings release: Q4 2023

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q4 2023


Tempest Therapeutics Annual report: Q4 2023

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Annual report: Q4 2023


Tempest Therapeutics Slides: Corporate Presentation

Nov 20, 2023, 5:00 AM EST - 2 years ago

Tempest Therapeutics Slides: Corporate Presentation


Tempest Therapeutics Quarterly report: Q3 2023

Nov 8, 2023, 4:00 PM EST - 2 years ago

Tempest Therapeutics Quarterly report: Q3 2023


Tempest Therapeutics Earnings release: Q3 2023

Nov 8, 2023, 4:00 PM EST - 2 years ago

Tempest Therapeutics Earnings release: Q3 2023


Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop


Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain


josegodoy
josegodoy Jul. 4 at 11:04 AM
$TPST no one knows where she’s going, PERIOD on the daily candle - looking for a break of the red descending line - this goes below $1 significantly (IMO) What was the October 2023 low….$0.23?…whatever If you need to write down why you bought this and have it front and center (read it daily) NO ONE KNOWS WHERE SHE’S GOING, PERIOD An opinion
0 · Reply
lousjamsession
lousjamsession Jul. 4 at 5:52 AM
0 · Reply
HectorNumba9
HectorNumba9 Jul. 3 at 4:52 PM
$TPST I dont see dilution. I see it moving with the economy. If u are here for a pump. You're in the wrong fucking stock😂😂😂i told u 100 times. Its buyout or die OMG I repeat
2 · Reply
lousjamsession
lousjamsession Jul. 3 at 1:25 PM
3 · Reply
joeydidntknowie
joeydidntknowie Jul. 2 at 10:30 PM
$TPST my take on this stock basically is with a significant catalyst it could really move. It has before. Until the catalyst happens there will probably be more pain in the form of dilution that we are accustomed to. I’ve decided to accumulate shares and average down because I believe in the value of the assets but I could definitely be completely wrong. People speculate as to the timing. Well …if only we knew. And it could be that the value of the assets isn’t much in which case we are in for a dilution mill — I doubt it but it’s possible. High risk high reward.
0 · Reply
josegodoy
josegodoy Jul. 2 at 9:41 PM
$TPST NO ONE KNOWS WHERE SHE’S GOING (period) Charts - simple line WEEKLY Chart I: the sign? - small break of the descending trend-line and too weak to break back (up) above it (too weak to even attempt to break back above it) - is it the tell of the up coming discount? = YES (my opinion) Chart II: the work up - I expect a significant discount over the next 8-10 weeks (in fact, I think we’ve already enter into it) THE RECOVERY 1) Historic: early-to-mid October holds historic significance (in terms of recovery) - positive data read-out 2) chart based ESTIMATE: approx Week of august 10 (recovery)….historically, recovery for this puppy means 4,000% - anticipated asset sale
2 · Reply
lousjamsession
lousjamsession Jul. 2 at 5:32 PM
$TPST @joeydidntknowie @WallStreetIsNotEasy
1 · Reply
joeydidntknowie
joeydidntknowie Jul. 2 at 5:11 AM
$TPST I hold 100k shares in this stock as of now. I have averaged down over months. I’m down about $50K. I’m not buying more and I’m not selling. We will see.
5 · Reply
josegodoy
josegodoy Jul. 1 at 8:43 PM
$TPST Just blocked Michl2000
3 · Reply
lgb2
lgb2 Jul. 1 at 4:48 PM
$TPST Tempest therapeutics names the tooth fairy as CEO
1 · Reply
josegodoy
josegodoy Jun. 30 at 10:54 PM
$TPST watching carefully (subtly moving “as expected”) - will chart it this weekend (give it a couple more days to develop) - I expect a discount (but NO ONE REALLY KNOWS where she’s going)
1 · Reply
TwongStocks
TwongStocks Jun. 30 at 8:20 PM
$TPST Q2 is now in the books. At end of Q1, TPST reported Total Assets of $10.748M (including $1.805M cash) and Total Liabilities of $9.926M. Which put Stockholders' Equity at $822K ($10.748M - $9.926M). Need Equity above $2.5M to regain compliance with NASDAQ's minimum equity requirements. Since the end of Q1, they did a warrant inducement on May 29 that raised $2M in additional cash. However, this will probably not be enough to raise equity above $2.5M. So the 10-Q in August will likely not show compliance with the NASDAQ's equity requirement. They have until July 6 to submit a compliance plan to NASDAQ. If NASDAQ accepts the plan, they'll be given a 180 day compliance period to increase equity above $2.5M. If they can figure out a way to increase cash significantly by Sept 30 (end of Q3), then they might be able to demonstrate compliance in the Nov 10-Q filing.
1 · Reply
lousjamsession
lousjamsession Jun. 30 at 3:17 PM
$TPST volume is low. Float is low. I will buy within 4 months. Hope i don't miss the boat because this stock will blow the top off.
5 · Reply
NeverTilted
NeverTilted Jun. 30 at 1:43 PM
$TPST added
0 · Reply
lousjamsession
lousjamsession Jun. 30 at 12:26 AM
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 29 at 10:50 PM
$TPST Current Stock Price: $1.08
0 · Reply
Michl2000
Michl2000 Jun. 29 at 8:14 PM
$TPST $SLS-power hour was stronger
0 · Reply
Michl2000
Michl2000 Jun. 29 at 7:30 PM
$TPST power hour 💪💪💪😉
0 · Reply
Michl2000
Michl2000 Jun. 29 at 7:26 PM
$TPST barcoding ??? 😁
0 · Reply
Michl2000
Michl2000 Jun. 29 at 7:05 PM
$TPST 🤷🤷🤷
0 · Reply
Xamayca
Xamayca Jun. 29 at 3:57 PM
$TPST 3of the4 reasons cited for suspending study 1495 due to “new information seem unlikely issues related to toxicity, in efficacy, or administrative issues . I just don’t see that. The fourth basically comes down to the party involved with the molecule meaning ownership likely changed to a foreign entity like China if it’s number 4. Not saying the other 3 aren’t possible but that would be a huge surprise whereas number 4 would not
0 · Reply
Michl2000
Michl2000 Jun. 29 at 1:59 PM
0 · Reply